Target intelligence / Profile preview

G-protein signaling modulator 1 (GPSM1) (GPSM1)

Target
GPSM1
Molecular classification
G-protein signaling modulator, GoLoco motif-containing protein, Guanine nucleotide dissociation inhibitor
01

Overview

G-protein signaling modulator 1 (GPSM1), also known as Activator of G-protein signaling 3 (AGS3), is a critical regulatory protein that modulates G-protein-coupled receptor (GPCR) signaling pathways through a receptor-independent mechanism (UniProt Q86YR5). It contains four GoLoco motifs that specifically bind to the GDP-bound form of G-alpha-i subunits, acting as a guanine nucleotide dissociation inhibitor (GDI) (PMID: 10521335). By sequestering G-alpha-i-GDP, GPSM1 prevents its re-association with G-beta-gamma subunits, thereby prolonging G-beta-gamma-mediated signaling and inhibiting G-alpha-i-mediated inhibition of adenylyl cyclase (PMID: 11459833). Biologically, GPSM1 is involved in diverse processes such as spindle orientation during asymmetric cell division, macroautophagy, and the regulation of insulin secretion in pancreatic beta cells (PMID: 20639557, PMID: 25635391). In clinical contexts, dysregulation of GPSM1 has been implicated in the progression of various cancers, including glioblastoma and breast cancer, as well as in metabolic and neurodegenerative diseases (PMID: 32853456). Although no FDA-approved drugs currently target GPSM1, it is an area of active research for the development of small molecules or peptides that can modulate G-protein signaling in pathological states (PMID: 24107127).

Other names
Activator of G-protein signaling 3AGS3PAGS3
02

Mechanism of action

Acts as a guanine nucleotide dissociation inhibitor (GDI) for G-alpha-i subunits, stabilizing the GDP-bound state and preventing re-association with G-beta-gamma subunits.

03

Biological functions

Signal transductionCell cycleAutophagyInsulin secretionVesicle trafficking
04

Disease associations

CancerMetabolic disorderNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Potential for systemic toxicity due to broad expressionDisruption of normal cell divisionAlteration of basal G-protein signaling
06

Biomarkers

GPSM1 protein expressionGPSM1 mRNA levels

Beyond the preview

Go deeper on G-protein signaling modulator 1 (GPSM1) (GPSM1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on G-protein signaling modulator 1 (GPSM1) (GPSM1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call